Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Stopped early · Phase 2
Conditions studied: Platinum Sensitive Ovarian Cancer, Ovarian Cancer
In brief
This is a double-blind, randomized, parallel groups Phase II trial. Patients with platinum-sensitive advanced ovarian cancer, defined as a lack of progression by RECIST v1.1 criteria following completion of standard-of-care chemotherapy, including a minimum of 4 cycles of a platinum-containing regimen. Patients will be randomized to either the vaccine regimen with GM-CSF adjuvant or GM-CSF adjuvant alone as a control group. Treatment will be administered as a consolidation therapy within one year of the last administration of platinum, targeting the first remission.
Key facts
- Study ID
- NCT02978222
- Run by
- Marker Therapeutics, Inc.
- People needed
- 120
- Starts
- 2017-07-20
- Expected to finish
- 2020-01-15
- Last updated by the study team
- 2022-12-15
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- UAB Gynecology Oncology — Birmingham, Alabama, United States
- Mayo Clinic Cancer Center — Phoenix, Arizona, United States
- Women's Cancer Research Foundation — Newport Beach, California, United States
- The Stamford Hospital/Bennett Cancer Center — Stamford, Connecticut, United States
- Mayo Clinic Florida — Jacksonville, Florida, United States
- Mt. Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- Florida Cancer Specialist — West Palm Beach, Florida, United States
- Mayo Clinic Rochester — Rochester, Minnesota, United States
- Research Partners — Jackson, Mississippi, United States
- MidAmerica Division, Inc. c/o Research Medical Center — Kansas City, Missouri, United States
- University Of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Hematology/Oncology Lenox Hill Hospital — New York, New York, United States
- Duke University Medical Center — Durham, North Carolina, United States
- OHSU — Portland, Oregon, United States
- Abington Memorial Hospital — Abington, Pennsylvania, United States
- Tennessee Oncology/Sarah Cannon Research Institute — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.